Albireo

News

Acquisitive Ipsen builds again with $952m Albireo buy

French drugmaker Ipsen has continued a recent spate of deal-making with a $42-per-share offer to buy US biotech Albireo and its rare disease therapy Bylvay.

Views & Analysis

Q-and-A-Albireo’s-Ron-Cooper-on-bile-acid-modulation

Q&A: Albireo’s Ron Cooper on bile acid modulation

While bile acids might not be as trendy as gene editing, modulating them has potential for first-in-class therapies for liver diseases.

News

After setback, Rhythm gets good news on Imcivree from FDA

Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks